HOME >> BIOLOGY >> NEWS
Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer

PHILADELPHIA A therapeutic cancer vaccine has shown effectiveness when given alongside chemotherapy to patients with metastatic colorectal cancer in a phase II trial, according to researchers at Oxford BioMedica (UK) Ltd. The study found that six of the 17 metastatic colorectal cancer patients in the study showed tumor shrinkage, classified as complete or partial responses following independent expert review.

The study, reported in the August 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, was designed to demonstrate the safety and immunogenicity of the vaccine, called modified vaccinia Ankara-encoding 5T4 (TroVax), when used alongside standard chemotherapy. The research was funded by Oxford BioMedica which is developing the vaccine in partnership with Sanofi-Aventis.

Unlike preventative vaccines, such as the human papillomavirus vaccine to prevent cervical cancer, TroVax is a therapeutic vaccine, designed to stimulate the immune systems of patients who already have cancer. The vaccine consists of an attenuated (non-disease causing) version of the vaccinia virus modified to deliver the gene for 5T4, a protein found in many tumors.

The idea is that the modified virus enters cells, produces the tumor protein and stimulates the immune system, said lead study author Richard Harrop, Ph.D., vice president of clinical immunology at Oxford BioMedica. To give a vaccine alongside chemotherapy might seem counterintuitive, since chemotherapy can weaken the immune system, but our study shows that TroVax could be complementary to standard chemotherapy, enhancing the immune response to tumors.

The target of this immuno-therapy approach is a tumor antigen called 5T4, a protein embedded within the membrane of cancer cells. The protein is rarely found in normal tissues, but is produced at high levels by a wide range of human cancers, including colorectal, renal, gastric and ovarian. The
'"/>

Contact: Greg Lester
lester@aacr.org
267-646-0554
American Association for Cancer Research
1-Aug-2007


Page: 1 2 3

Related biology news :

1. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
2. Oncolytics Biotech Inc. proceeds to initiate US Phase II sarcoma clinical trial
3. The Parkinsons Institute to conduct Phase III Clinical Trial of creatine for Parkinsons disease
4. Phase III trials of cellulose sulfate microbicide for HIV prevention closed
5. Phylonix awarded National Science Foundation Phase II SBIR for zebrafish screening
6. Kentucky first state to match federal SBIR-STTR Phase 1 and Phase 2 grants
7. Acorda announces positive Phase 3 Fampridine-SR study in people with multiple sclerosis
8. REMICADE Phase 3 data show rapid, significant, long-term psoriasis improvement
9. New Phase 3 data show potential benefits of Aranesp dosed every three weeks for CIA
10. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
11. Centocor & Schering-Plough next generation biologic promising in Phase 2 rheumatoid arthritis trial

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
Breaking Biology News(10 mins):
(Date:6/28/2017)... 2017 (PRWEB) , ... June ... ... of Siemens’ STAR-CCM+® software for multiphysics computational fluid dynamics (CFD) simulation and ... exploration and optimization. STAR-CCM+ version 12.04 introduces Design Manager, allowing users to ...
(Date:6/27/2017)... ... June 27, 2017 , ... Brain State Technologies, ... Kickstarter campaign on June 15th to fund production of the new B2v2 wearable ... original Kickstarter goal by more than 150% in a little over a week. ...
(Date:6/27/2017)... ... June 27, 2017 , ... DuPont ... gains exclusive rights to the ERS patent portfolio covering CRISPR-Cas genome editing technology ... the foundational intellectual property (IP) of the CRISPR-Cas technology from co-inventor and co-owner ...
(Date:6/26/2017)... ... , ... Two new members were elected to the University City Science Center’s ... President, J Nowak Strategy and Michele Masucci, Ph.D., Vice President for Research Administration at ... and Kenneth L. Kring, and re-election of David P. Holveck and Richard P. Jaffe, ...
Breaking Biology Technology:
Cached News: